Veracyte gains after data supports Decipher test for hormone therapy in prostate cancer

Veracyte shares rose 1.6% premarket to $45.94 after it said its Decipher test identified intermediate-risk prostate cancer patients most likely to benefit from adding hormone therapy to radiation, citing retrospective analysis of 395 patients.